A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
Recruiting
TYK Medicines, Inc
Phase 1
2021-05-01
To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a
single fasting administration and the effect of food on the pharmacokinetics of TY-9591
tablets in healthy volunteers.
A Phase II/III Study of SI-B001 in Combination With Osimertinib in the Treatment of EGFR/ALK WT Recurrent and Metastatic NSCLC
Not yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/Phase 3
2021-10-01
Main purpose:
1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single
low dose combined with chemotherapy in patients with locally advanced or metastatic
NSCLC.
2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or
metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and
single-dose low-dose combination chemotherapy, and to select the optimal dose (combined
with RP2D) and mode of SI-B001 combined with chemotherapy.
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
Not yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/Phase 3
2021-10-01
Main purpose:
1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single
low dose combined with Osimertinib in patients with locally advanced or metastatic
NSCLC.
2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or
metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and
single-dose low-dose combination chemotherapy, and to select the optimal dose (combined
with RP2D) and mode of SI-B001 combined with Osimertinib.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
